NT-501 CNTF Implant

COMBINATION_PRODUCT4 trials

Sponsors

Jeffrey L Goldberg, Neurotech Pharmaceuticals

Conditions

Glaucoma, Primary Open AngleIschemic Optic Neuropathy/Optic Nerve StrokeMacular Telangiectasia Type 2

Phase 1

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

CompletedNCT01408472

Jeffrey L GoldbergGlaucoma, Primary Open Angle

Start: 2011-04-30End: 2014-10-31Updated: 2016-08-02

NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement

CompletedNCT01411657

Jeffrey L GoldbergIschemic Optic Neuropathy/Optic Nerve Stroke

Start: 2011-04-30End: 2014-10-31Updated: 2016-08-02

Phase 2

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

CompletedNCT04729972

Neurotech PharmaceuticalsMacular Telangiectasia Type 2

Start: 2021-07-21End: 2022-12-08Updated: 2025-03-26

Phase 3

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Active, not recruitingNCT06397131

Neurotech PharmaceuticalsMacular Telangiectasia Type 2

Start: 2025-03-06End: 2026-07-24Updated: 2025-07-10

Related Papers

Role of animal models in glaucoma research

Neural Regeneration Research2020-01-0113 citations

Neurotrophic factors: promising candidates in tissue regeneration

Neural Regeneration Research2016-01-0113 citations